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Álvaro Nagib AtallahAngiotensin-converting enzyme 
inhibitors during the fi rst trimester 
of pregnancy increase the incidence 
of fetal malformation, whereas 
calcium intake (1.0 to 2.0 g/day) 
prevents preeclampsia* 
A retrospective study on 29,507 pregnant women pub-
lished in the New England Journal of Medicine in June 2006 
showed that the use of angiotensin-converting enzyme (ACE) 
inhibitors during the fi rst trimester of pregnancy increased 
the risk of major fetal malformation. The estimated risk ratio 
was 2.71, with a 95% confi dence interval (CI) of 1.72-4.27, in 
comparison with patients who did not receive anti-hypertensive 
medication. Other hypertensive drugs utilized during the 
same period of pregnancy did not increase the risk of 
malformation.1
The fetuses exposed to ACE inhibitors presented around 
three to four times greater risk of cardiovascular malformation 
(risk ratio: 3.72; 95% CI: 1.89-7.30) and of central nervous 
system malformation (risk ratio: 4.39; 95% CI: 1.97-14.02). 
The authors concluded that exposing pregnant women to ACE 
inhibitors during the fi rst trimester of pregnancy was unsafe 
and must be avoided. Other studies had already demonstrated 
fetal risks in using ACE inhibitors during the second and third 
trimesters of pregnancy.
The conclusions from the study described here and from 
previous studies are categorical and it would be diffi cult for any-
one to take an interest in conducting clinical studies on a drug 
to increase the certainty that it causes fetal malformation.
In order to establish whether a new treatment is better than 
a previous one (i.e. that it is generally effective), high-quality 
“megatrials” are needed. But to recommend the exclusion of a 
drug for which the potential risk is very high and unacceptable, 
a lower level of evidence is suffi cient, which in this case was a 
retrospective observational study. It is just a question of good 
sense. And particularly because there are other alternatives for 
treating arterial hypertension during pregnancy that are safer, 
such as alpha-methyldopa and hydralazine.
If we consider that we need evidence in order to know what 
may work and what may not work, this question just needs to 
be answered rationally. For a long time, we had been reading 
articles saying that there is no evidence that ACE inhibitors 
cause malformations during the fi rst trimester of pregnancy. 
Well, now there is. Lack of evidence does not signify absence 
of effects. Such effects may be good or bad. Hence the need 
for us to group together reliable scientifi c data (randomized 
clinical trials and systematic reviews) before we expose mothers, 
fetuses, sons, daughters, fathers, siblings, friends and children 
of God in general, to uncalculated risks. It can be seen that, in 
this case, because of the lack of evidence from previous clinical 
trials regarding the use of this drug during pregnancy, many 
fetuses developed serious malformations. The mistake of not 
researching the safety of treatments before implementing them 
has been repeated ad nauseam.
Calcium supplementation 
during pregnancy 
The systematic review on calcium supplementation 
published in the Cochrane Library has been updated with a 
new clinical trial. The latest edition of the review presents a total 
of almost 15,000 cases studied, through the addition of a large 
clinical trial that was motivated by the publication of an earlier 
edition of this review. The new trial included was funded by 
the World Health Organization (WHO) and was conducted 
by researchers in several countries. The review is now more 
robust and reliable, and shows that the use of calcium during 
* This editorial was also published in Portuguese in the journal Diagnóstico & Tratamento, volume 11, issue no. 4, October to December, 2006.
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pregnancy among at-risk mothers with low calcium intake reduces the 
incidence of preeclampsia by 50%. Moreover, calcium use decreases 
the incidence of outcomes consisting of death or serious morbidity. No 
risks to the mother or fetus were demonstrated through calcium use.
Implications 
In summary, an observational study has shown what must not be 
done: prescribing of ACE inhibitors during the fi rst trimester of preg-
nancy (or maintaining such prescriptions after detecting pregnancy). On 
the other hand, a systematic review enriched by a megatrial has shown 
what must be done to reduce maternal-fetal risks: calcium supplementa-
tion. In this way, human health will improve from the outset of uterine 
life onwards, thanks to good medical science. 
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